https://www.selleckchem.com/pr....oducts/camostat-mesi
We examined whether chronic kidney disease (CKD) modifies the frequency of heart failure hospitalisation (HHF) relative to atherosclerotic major adverse cardiovascular events (MACE; composite of cardiovascular death, myocardial infarction [MI], or stroke) in people with type 2 diabetes. Of 16 cardiovascular outcomes trials in type 2 diabetes since 2013, seven reported outcomes stratified by estimated glomerular filtration rate (eGFR) category (60 vs. ≥60 mL/min/1.73 m ), and five by albuminuria status. Placebo-arm
Like
Comment
Share
